Numerate and Boehringer Ingelheim (Canada) Form Research Collaboration Based on in silico Drug Design Technology
Drug Discovery Research to Focus on Infectious Disease Target
SAN BRUNO, Calif., Dec 06, 2011 (BUSINESS WIRE) -- Numerate, Inc., a technology platform company that is leveraging the power of cloud computing and novel computational methods to transform the drug design process, announced today that it has entered into a research collaboration with Boehringer Ingelheim (Canada) Ltd. The collaboration will utilize Numerate's proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed infectious disease target.
"Using our large-scale computational drug design methods, we expect to greatly reduce the time and cost of delivering new lead-stage, small molecule drug candidates in this important program for Boehringer Ingelheim," stated Numerate chief executive officer Guido Lanza. "This collaboration is the latest in our growing number of partnerships with pharmaceutical companies that are looking to Numerate's comprehensive in silico drug design technology to help them increase their success rate in generating novel, patentable small molecule leads."
Numerate's drug design platform features a set of proprietary algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing. Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.
Numerate is a privately held biotechnology company pioneering new computational methods for making the drug design process more data-driven, efficient and predictable. Numerate's in silico drug design platform combines proprietary algorithms and cloud computing with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields. For more information, please visit www.numerate.com (corporate site) and www.numerati.com (technical site).
SOURCE: Numerate, Inc.
Guido Lanza, 650-515-4387
Chief Executive Officer